Infinite Epigenetics announced its acquisition of Tally Health, expanding its capabilities across epigenetic diagnostics, adult DNA methylation datasets, and personalized intervention offerings. The deal is structured to bring together measurement-focused data assets with downstream “personalized” health programs aimed at improving healthspan. For the epigenetic diagnostics space, the transaction signals consolidation around large-scale methylation datasets and translation into actionable health recommendations. The acquired platform elements—diagnostics plus intervention layers—are intended to strengthen differentiation in a market where clinicians and consumers increasingly ask for practical endpoints beyond biomarker readouts. Details on financial terms and specific integration timelines were not included in the excerpted report, but the direction is clear: turn methylation analytics into a more complete workflow for end users.